Headache News and Research RSS Feed - Headache News and Research

In medicine a headache or cephalalgia is a symptom of a number of different conditions of the head. Some of the causes are benign while others are medical emergencies.
Further Reading

First Edition: March 28, 2014

The White House said on Thursday that more than six million people had signed up for medical insurance plans under President Obama's health care law, exceeding the administration's revised goal for enrollment by the Monday deadline. [More]
CDC identifies six new cases of people with Heartland virus

CDC identifies six new cases of people with Heartland virus

The Centers for Disease Control and Prevention in collaboration with health officials in Missouri and Tennessee have identified six new cases of people sick with Heartland virus: five in Missouri and one in Tennessee. The new cases, discovered in 2012 and 2013, are described today in CDC's Morbidity and Mortality Weekly Report. [More]
Study highlights importance of stress management, healthy lifestyle habits for people with migraine

Study highlights importance of stress management, healthy lifestyle habits for people with migraine

Migraine sufferers who experienced reduced stress from one day to the next are at significantly increased risk of migraine onset on the subsequent day, according to a new study conducted by researchers at the Montefiore Headache Center and Albert Einstein College of Medicine at Yeshiva University. [More]

Viewpoints: Be careful what you pray for; health law 'freakouts;' concerns about imported drugs

On Tuesday, the Supreme Court will consider a proposition that will strike many Americans as bizarre: that large, for-profit businesses can refuse on religious grounds to comply with a federal mandate that they include contraception in their employee health plans (3/25). [More]
Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Today Biogen Idec announced that Health Canada has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. [More]
Elsevier launches Open Access, online-only journal Internet Interventions

Elsevier launches Open Access, online-only journal Internet Interventions

Elsevier, a world-leading provider of scientific, technical and medical (STM) information products and services, is pleased to announce the launch of the Open Access, online-only journal Internet Interventions. [More]

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Medivir AB today announced that new phase III data for the once-daily protease inhibitor simeprevir have been presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Brisbane, Australia. [More]

Study of high school players find no link between years of play and decline in neurocognitive function

As more parents consider whether it's safe for adolescents to play football, a new Tulane University study of high school players found no link between years of play and any decline in neurocognitive function. [More]
Study finds no link between neurocognitive function and years of football play in adolescent athletes

Study finds no link between neurocognitive function and years of football play in adolescent athletes

A new study presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons found no link between neurocognitive function and years of football play in adolescent athletes. [More]

New insights into how human brain responds to chronic pain

University of Adelaide researchers say new insights into how the human brain responds to chronic pain could eventually lead to improved treatments for patients. [More]

Cefaly medical device receives FDA approval for migraine prevention

CEFALY Technology announced today that its received U.S. Food and Drug Administration approval of the Cefaly medical device for the preventative treatment for migraine headaches. Cefaly is the first transcutaneous electrical nerve stimulation (TENS) device specifically authorized for use prior to the onset of pain. It is expected to be available in the U.S. in early April. [More]

Orexo signs multi-year agreement with OptumRx and UnitedHealth Group

Orexo AB, the manufacturer of ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII), announced a multi-year agreement with UnitedHealth Group® and OptumRx® providing preferred coverage and reimbursement of ZUBSOLV®. [More]
Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. [More]

Conditioned pain modulation decreases activity in human spinal cord, say researchers

Researchers have demonstrated that conditioned pain modulation (CPM), a measure of the brain's ability to regulate pain, decreases activity in the human spinal cord as visible via functional magnetic resonance imaging (fMRI). [More]
Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation (Nasdaq: INCY) today announced that a pivotal Phase III trial of ruxolitinib compared to best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea has met its primary endpoint of achieving phlebotomy independence and reducing spleen size by 35 percent or more. [More]

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Today Boehringer Ingelheim announced results from STARTVerso4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg faldaprevir dose groups. [More]

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor. [More]
Loyola physician sheds light on common and painful viral infection, shingles

Loyola physician sheds light on common and painful viral infection, shingles

Shingles is a painful viral infection that affects almost one million people worldwide and 30 percent of Americans every year. [More]

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

The first detailed results from AbbVie's pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4. [More]

Dendreon plans to make PROVENGE available in Europe

Dendreon Corporation today announced that it plans to make PROVENGE (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom. [More]